LIWANLI Innovation Co., Ltd. Stocks

NT$ 75.7Last Updated 17.04.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 194.03M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 75.7
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience. Its products include probiotic enzymes, pro-active nutrients, resveratrol red grape extract, algae DHA soft gels, shea butter with type II collagen soft gels, algae astaxanthin Q10 soft gels, cordyceps militaries powder, tooth guard tablets, bovine and goat's milk bites, bilberry-tablets, DHA and vitamin D3 drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is based in New Taipei City, Taiwan.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks